Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Overcoming endocrine resistance in breast cancer
Estrogen receptor-positive (ER+) breast cancer is the most common breast cancer subtype.
Treatment of ER+ breast cancer comprises interventions that suppress estrogen production …
Treatment of ER+ breast cancer comprises interventions that suppress estrogen production …
[HTML][HTML] PI3K/AKT/mTOR-targeted therapy for breast cancer
K Zhu, Y Wu, P He, Y Fan, X Zhong, H Zheng, T Luo - Cells, 2022 - mdpi.com
Phosphatidylinositol 3-kinase (PI3K), protein kinase B (PKB/AKT) and mechanistic target of
rapamycin (mTOR)(PAM) pathways play important roles in breast tumorigenesis and confer …
rapamycin (mTOR)(PAM) pathways play important roles in breast tumorigenesis and confer …
Insights for precision oncology from the integration of genomic and clinical data of 13,880 tumors from the 100,000 Genomes Cancer Programme
Abstract The Cancer Programme of the 100,000 Genomes Project was an initiative to
provide whole-genome sequencing (WGS) for patients with cancer, evaluating opportunities …
provide whole-genome sequencing (WGS) for patients with cancer, evaluating opportunities …
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on …
Background In the PALOMA-3 study, the combination of the CDK4 and CDK6 inhibitor
palbociclib and fulvestrant was associated with significant improvements in progression-free …
palbociclib and fulvestrant was associated with significant improvements in progression-free …
The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes
The genomic landscape of breast cancer is complex, and inter-and intra-tumour
heterogeneity are important challenges in treating the disease. In this study, we sequence …
heterogeneity are important challenges in treating the disease. In this study, we sequence …
Is cancer biology different in older patients?
Y Van Herck, A Feyaerts, S Alibhai… - The Lancet Healthy …, 2021 - thelancet.com
Roughly 50% of cancer cases occur in people aged 65 years or older. Older people are
often diagnosed at a later stage and might receive less (intensive) treatment, which might …
often diagnosed at a later stage and might receive less (intensive) treatment, which might …
[HTML][HTML] Targeting PI3K/AKT/mTOR signaling pathway in breast cancer
Simple Summary PI3K signaling pathway plays an essential role in many cellular processes
and is frequently altered in breast cancer, leading to increased tumor growth and reduced …
and is frequently altered in breast cancer, leading to increased tumor growth and reduced …
Targeting PI3K/AKT/mTOR pathway in breast cancer: From biology to clinical challenges
Breast cancer (BC) is the most common women cancer and cause of cancer death. Despite
decades of scientific progress in BC treatments, the clinical benefit of new drugs is modest in …
decades of scientific progress in BC treatments, the clinical benefit of new drugs is modest in …
Distinct functions of AKT isoforms in breast cancer: a comprehensive review
Background AKT, also known as protein kinase B, is a key element of the PI3K/AKT
signaling pathway. Moreover, AKT regulates the hallmarks of cancer, eg tumor growth …
signaling pathway. Moreover, AKT regulates the hallmarks of cancer, eg tumor growth …
Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer
Background α-Selective phosphatidylinositol 3-kinase (PI3K) inhibitors improve outcome in
patients with PIK3CA-mutated, hormone receptor-positive (HR+)/Her2− metastatic breast …
patients with PIK3CA-mutated, hormone receptor-positive (HR+)/Her2− metastatic breast …